| Date | Title | Description | |
|---|---|---|---|
| 23 Feb 2022 | Annual Report regarding remuneration of the members of the Board of Directors | ROVI releases the 2021 annual report regarding remuneration of the members of the Board of Directors | Download |
| 23 Feb 2022 | Annual Corporate Governance Report | ROVI releases the 2021 Annual Corporate Governance Report | Download |
| 21 Feb 2022 | Share buy-back , stabilisation and treasury stock programme | Share Buyback Program: transactions conducted between 14 February 2022 and 21 February 2022 | Download |
| 15 Feb 2022 | On business and financial situation | ROVI has announced that the European Commission has authorised the marketing of Okedi® for the treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone. | Download |
| 14 Feb 2022 | Share buy-back , stabilisation and treasury stock programme | Share Buyback Program: transactions conducted between 7 February 2022 and 11 February 2022 | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 06 Nov 2018 | Información sobre resultados | ROVI releases the presentation related to the nine-month period ended 30 September 2018 results. | Download |
| 06 Nov 2018 | Información sobre resultados | ROVI releases the press release related to the nine-month period ended 30 September 2018 results. | Download |
| 17 Oct 2018 | Buy-back programmes, stabilisation and treasury stock | ROVI informs of the resumption of operations with own shares under the liquidity contract | Download |
| 17 Oct 2018 | Buy-back programmes, stabilisation and treasury stock | ROVI informs that Jefferies International Limited has exercised, in full, the greenshoe subscription option | Download |
| 08 Oct 2018 | Share capital increases and reductions | Information on new shares admissions related to the capital increase of ROVI | Download |